ClinicalTrials.gg
CompletedNCT01431339Updated Feb 12, 2014Results posted

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3 interventional study of IV Dalbavancin and Vancomycin/Linezolid in Abscess, Wound Infection and Surgical Site Infection, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 137 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-02-12.

Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
739
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Abscess with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Abscess · United States.

Enrollment
8th of 75
739 · median 114
Started
2011
with 5 others
Phase 3
13 of 80
none open now
Registered
40th of 80
by date
Lead sponsor
3 of 80
Durata Therapeutics Inc., an affiliate of Allergan plc

Among the 80 studies in Abscess with a site in United States, this one is the 8th largest by enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 40th registered.

Abscess

152 studies on the registry are indexed under Abscess; 22 are open to participants now.

Browse Abscess studies →

Open to participants now

4 of the 80 studies in Abscess with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Abscess studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Abscess with a site in United States, or all of them as a file.
02

Study summary

The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.

03

Conditions studied

  • Abscess
  • Wound Infection
  • Surgical Site Infection
  • Cellulitis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 - 85 years of age.
  2. Signed and dated document.
  3. Major abscess, surgical site infection, traumatic wound infection or cellulitis suspected or confirmed to be caused by Gram-positive bacteria.
  4. At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign of infection.
  5. Requires a minimum of 3 days of IV therapy.
  6. Patient willing and able to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

Patients presenting with any of the following:

  1. A to any required study drug.
  2. Pregnant or nursing females.
  3. Sustained shock.
  4. Participation in another study of an drug or device within 30 days.
  5. Receipt of a systemically or topically administered antibiotic within 14 days prior to randomization, except receipt of a single dose of a short-acting antibacterial drug 3 or more days prior to randomization.
  6. Infection due to a dalbavancin or vancomycin-resistant organism.
  7. Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, and/or endovascular infection.
  8. Exclusively gram-negative bacterial or a fungal ABSSSI.
  9. Venous catheter infection.
  10. Infection of a diabetic foot ulcer or a decubitus ulcer.
  11. Device-related infections.
  12. Gram-negative bacteremia.
  13. Infected burns.
  14. Infected limb with critical ischemia.
  15. Superficial/simple skin and skin structure infections.
  16. Concomitant condition requiring non-study antibacterial therapy.
  17. ABSSSI requiring therapy for longer than 14 days.
  18. Adjunctive therapy with hyperbaric oxygen.
  19. More than 2 surgical interventions for ABSSSI anticipated.
  20. Chronic inflammatory condition precluding assessment of clinical response.
  21. \< 500 cells/mm3.
  22. (HIV) infection with a \< 200 cells/mm3.
  23. Recent bone marrow transplant, > 20 mg prednisolone per day (or equivalent) or receiving drugs after organ transplantation.
  24. Regular, chronic antipyretic use in patients unable to modify during the first three days of study drug therapy.
  25. less than 3 months.
  26. Conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.
  27. Prior participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
739 participants (actual)

Study arms

  • Active comparator
    Vancomycin with possible switch to oral linezolid

    Drug: Vancomycin/Linezolid

  • Experimental
    Dalbavancin

    Drug: IV Dalbavancin

Interventions

06

What researchers measure

Primary outcomes

  1. Early Clinical Efficacy

    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature

    Time frame: After 48-72 hours of therapy

Secondary outcomes

  1. Clinical Status

    Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy

    Time frame: End of Treatment Visit (Day 14-15)

  2. >= 20% Reduction in Lesion Area

    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size

    Time frame: 48-72 hours after the initiation of study therapy

  3. Clinical Status

    Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy

    Time frame: Follow-Up Visit (day 28)

07

Results

Posted Feb 12, 2014

Participant flow

Participant flow — Overall Study
MilestoneDalbavancinVancomycin With Possible Switch to Oral Linezolid
Started371368
Safety population368367
Completed332333
Not completed3935

Outcome measures

PrimaryEarly Clinical Efficacy

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature

Time frame:
After 48-72 hours of therapy
Reported as:
Number · participants
Early Clinical Efficacy
participantsDalbavancinVancomycin With Possible Switch to Oral Linezolid
Clinical Responder285288
Clinical Non-Responder8680
Statistical analysis
  • Dalbavancin vs Vancomycin With Possible Switch to Oral Linezolid · Difference in proportions: -1.5 · 95% CI -7.4 to 4.6Confidence intervals were adjusted for fever at baseline
SecondaryClinical Status

Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy

Time frame:
End of Treatment Visit (Day 14-15)
Reported as:
Number · participants
Clinical Status
participantsDalbavancinVancomycin With Possible Switch to Oral Linezolid
Clinical Succcess303280
Clinical Failure2122
Secondary>= 20% Reduction in Lesion Area

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size

Time frame:
48-72 hours after the initiation of study therapy
Reported as:
Number · participants
>= 20% Reduction in Lesion Area
participantsDalbavancinVancomycin With Possible Switch to Oral Linezolid
Clinical Responder325316
Clinical Non-Responder4652
SecondaryClinical Status

Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy

Time frame:
Follow-Up Visit (day 28)
Reported as:
Number · participants
Clinical Status
participantsDalbavancinVancomycin With Possible Switch to Oral Linezolid
Clinical Success283257
Clinical Failure1115

Adverse events

Collected over Begins from the time that the patient provides informed consent through the last follow up visit, Day 70. Any SAE occurring any time after the reporting period must be promptly reported if a causal relationship to investigational product is suspected.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dalbavancin—12/368 (3.3%)29/368 (7.9%)
Vancomycin With Possible Switch to Oral Linezolid—14/367 (3.8%)28/367 (7.6%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventDalbavancinVancomycin With Possible Switch to Oral Linezolid
CellulitisInfections and infestations3/3680/367
GangreneInfections and infestations0/3682/367
Systemic inflammatory response syndromeGeneral disorders0/3681/367
ErythemaSkin and subcutaneous tissue disorders0/3681/367
Blood glucose increasedInvestigations0/3681/367
AbscessInfections and infestations0/3681/367
Cholecystitis acuteHepatobiliary disorders0/3681/367
Gastrointestinal disorderGastrointestinal disorders0/3681/367
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/3681/367
Renal failure acuteRenal and urinary disorders0/3681/367
Most frequent other events
Most frequent other events
EventDalbavancinVancomycin With Possible Switch to Oral Linezolid
NauseaGastrointestinal disorders15/36815/367
HeadacheNervous system disorders11/3689/367
DiarrhoeaGastrointestinal disorders4/3688/367
VomitingGastrointestinal disorders8/3684/367

Baseline characteristics

Age, Continuous
Age, Continuous(years)DalbavancinVancomycin With Possible Switch to Oral LinezolidTotal
Mean49.1 ± 16.5451.4 ± 16.1650.2 ± 16.38
Sex: Female, Male
Sex: Female, Male(Participants)DalbavancinVancomycin With Possible Switch to Oral LinezolidTotal
Female148167315
Male223201424
08

Study locations

137 sites
  • Durata Clinical Site
    Montgomery, Alabama 36106, United States
  • Durata Clinical Site
    Anaheim, California 92804, United States
  • Durata Clinical Site
    Buena Park, California 90620, United States
  • Durata Study Site
    Chula Vista, California 91911, United States
  • Durata Clinical Site
    Long Beach, California 90813, United States
  • Durata Study Site
    Los Angeles, California 90015, United States
  • Durata Study Site
    Norwalk, California 90650, United States
  • Durata Study Site
    Oxnard, California 93030, United States
  • Durata Study SIte
    San Diego, California 92120, United States
  • Durata Study Site
    Stockton, California 95204, United States
  • Durata Clinical Site
    Boyton Beach, Florida 33435, United States
  • Durata Clinical Site
    Ft. Meyers, Florida 33966, United States
  • Durata Clinical Site
    Miami, Florida 33015, United States
  • Durata Study Site
    Orlando, Florida 32837, United States
  • Durata Clinical Site
    St. Cloud, Florida 34769, United States
  • Durata Clinical Site
    Augusta, Georgia 30901, United States
  • Durata Study Site
    Columbus, Georgia 31904, United States
  • Durata Clinical Site
    Chicago, Illinois 60637, United States
  • Durata Study Site
    Baton Rouge, Louisiana 70809, United States
  • Durata Study Site
    New Orleans, Louisiana 70112, United States
  • Durata Study Site
    Shreveport, Louisiana 71101, United States
  • Durata Study Site
    Zachary, Louisiana 70791, United States
  • Durata Study Site
    Las Vegas, Nevada 89109, United States
  • Durata Study Site
    Springfield, Ohio 45502, United States
  • Durata Study Site
    Philadelphia, Pennsylvania 19103, United States
  • Durata Study Site
    Austin, Texas 78701, United States
  • Durata Clinical Site
    Austin, Texas 78752, United States
  • Durata Clinical Site
    Houston, Texas 77055, United States
  • Durata Study Site
    Richmond, Texas 77469, United States
  • Durata Study Site
    Middleton, Wisconsin 53562, United States
  • Durata Study Site
    Pleven, 5800, Bulgaria
  • Durata Study Site
    Plovdiv, 4000, Bulgaria
  • Durata Study Site
    Sevlievo, 5400, Bulgaria
  • Durata Study Site
    Sofia, 1000, Bulgaria
  • Durata Study Site
    Sofia, 1407, Bulgaria
  • Durata Study Site
    Sofia, 1431, Bulgaria
  • Durata Study Site
    Sofia, 1606, Bulgaria
  • Durata Study Site
    Kohtla-Jarve, 30322, Estonia
  • Durata Clinical Site
    Kohtla-Jarve, Estonia
  • Durata Clinical Site
    Tallinn, 10136, Estonia
  • Durata Clinical Site
    Tallinn, 13419, Estonia
  • Durata Study Site
    Tartu, 51014, Estonia
  • Durata Study Site
    Budapest, H-1081, Hungary
  • Durata Clinical Site
    Budapest, Hungary
  • Durata Study Site
    Debrecen, H-4043, Hungary
  • Durata Clinical Site
    Kaposvar, H-7400, Hungary
  • Durata Clinical SIte
    Pecs, H-7624, Hungary
  • Durata Clinical Site
    Szeged, H-6720, Hungary
  • Durata Study Site
    Veszprem, H-8200, Hungary
  • Durata Clinical Site
    Haifa, 31906, Israel
  • Durata Study Site
    Jerusalem, 91120, Israel
  • Durata Clinical Site
    Kfar Saba, 44281, Israel
  • Durata Study Site
    Petach Tikva, 49100, Israel
  • Durata Clinical Site
    Petah-Tiqva, 49100, Israel
  • Durata Clinical Site
    Ramat-Gan, 52621, Israel
  • Durata Study Site
    Tel Aviv, 64239, Israel
  • Durata Clinical Site
    Jung Gu, Daegu 700-721, Korea, Republic of
  • Durata Clinical Site
    Ansan, 425-707, Korea, Republic of
  • Durata Study Site
    Daejeon, 301721, Korea, Republic of
  • Durata Study Site
    Gwangju, 501-757, Korea, Republic of
  • Durata Clinical Site
    Incheon, 405-760, Korea, Republic of
  • Durata Clinical Site
    Kangwon-do, 220-71, Korea, Republic of
  • Durata Study Site
    Seoul, 133-791, Korea, Republic of
  • Durata Clinical Site
    Seoul, 134-701, Korea, Republic of
  • Durata Study Site
    Seoul, 134-701, Korea, Republic of
  • Durata Study Site
    Seoul, 135-710, Korea, Republic of
  • Durata Clinical Site
    Seoul, 136-705, Korea, Republic of
  • Durata Study Site
    Seoul, 138-736, Korea, Republic of
  • Durata Clinical Site
    Seoul, 152-703, Korea, Republic of
  • Durata Clinical Site
    Daugavpils, LV-5417, Latvia
  • Durata Clinical Site
    Liepaja, LV-3414, Latvia
  • Durata Study Site
    Rezekne, LV-4600, Latvia
  • Durata Study Site
    Riga, LV-1001, Latvia
  • Durata Clinical Site
    Riga, LV-1002, Latvia
  • Durata Clinical Site
    Ventspils, LV-3601, Latvia
  • Durata Clinical Site
    Kaunas, LT-45130, Lithuania
  • Durata Clinical Site
    Kauno m. sav, LT-47144, Lithuania
  • Durata Clinical Site
    Klaipėda, LT-76231, Lithuania
  • Durata Clinical Trial
    Vilnius, LT-10207, Lithuania
  • Durata Clinical Site
    Šiauliai, LT-76231, Lithuania
  • Durata Study Site
    Bucharest, 010713, Romania
  • Durata Clinical Site
    Bucharest, 010825, Romania
  • Durata Study Site
    Bucharest, 011461, Romania
  • Durata Clinical Trial
    Bucharest, 042122, Romania
  • Durata Study Site
    Bucharest, 75622, Romania
  • Durata Clinical Site
    Burcharest, 020125, Romania
  • Durata Study Site
    Cluj-Napoca, 400006, Romania
  • Durata Study Site
    Constanta, 900709, Romania
  • Durata Study Site
    Targu Mures, 540072, Romania
  • Durata Clinical Site
    Timisoara, 300736, Romania
  • Durata Clinical Site
    Vsevolozhsk, Leningrad Region 188640, Russian Federation
  • Durata Study Site
    Vsevolozhsk, Leningrad 188864, Russian Federation
  • Durata Study Site
    Moscow, 111539, Russian Federation
  • Durata Clinical Site
    Moscow, 115280, Russian Federation
  • Durata Study Site
    Petrozavodsk, 18519, Russian Federation
  • Durata Clinical Site
    Smolensk, 214018, Russian Federation
  • Durata Clinical Site
    St. Petersburg, 198099, Russian Federation
  • Durata Study Site
    Tomsk, Russian Federation
  • Durata Clinical Site
    Tver, 170036, Russian Federation
  • Durata Clinical Site
    Volgograd, 400138, Russian Federation

Showing the first 100 of 137 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials. Infect Dis Ther. 2022 Feb;11(1):423-434. doi: 10.1007/s40121-021-00568-7. Epub 2021 Dec 14. PubMed 34905144 ↗
  • Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480. PubMed 24897082 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 9, 2011
Start
Jul 2011
Primary completionActual
Nov 2012
CompletionActual
Dec 2012
Results first posted
Feb 12, 2014
Last update
Feb 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431339
Responsible party
Sponsor
First posted
Sep 9, 2011
Start date
Jul 2011
Primary completion
Nov 2012
Completion
Dec 2012
Results posted
Feb 12, 2014
Last update
Feb 12, 2014

Study contacts

Michael Dunne, MD
study director · Durata Therapeutics Inc., an affiliate of Allergan plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalbavancin

Start the discussion